Study Condition(s): Soft Tissue Sarcoma

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Study Alias: JGDM

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02783599 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Your participation could last up to 25 weeks depending on how you and your tumor respond.
  • Participant must have a diagnosis of Soft Tissue Sarcoma (STS) confirmed by histology
  • Participant must have a diagnosis of STS of the extremities confirmed by histology for radiotherapy addendum
  • Participant must not have Kaposi's sarcoma or gastrointestinal stromal tumors (GIST) or myxoid liposarcoma in radiotherapy addendum
  • Participant must agree to undergo 2 mandatory tissue biopsies for the main study. For radiotherapy addendum archived tissue samples may be acceptable
  • Participant must not have active central nervous system (CNS) or leptomeningeal metastasis (brain metastasis) at the time of enrollment
  • Participant must not have received prior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines or anthracenediones
    • Participants must not have received prior radiotherapy treatment in the primary tumor for radiotherapy addendum
  • Participant must not have received treatment with olaratumab or have participated in a prior olaratumab trial

Where to Participate

13 locations are currently available of 13 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.